Elevation of interferon type I (IFN-I) is associated with more severe disease in patients with systemic lupus erythematosus (SLE), although the relationship between elevated levels of IFN-I and SLE disease activity over time has not been defined.
Lupus nephritis is frequently associated with a poor long-term prognosis in patients with systemic lupus erythematosus (SLE).
Disease-specific patient-reported outcome (PRO) tools would be useful in the management of a number of rheumatologic conditions, including rheumatoid arthritis (RA), psoriatic arthritis, and systemic lupus erythematosus (SLE).
The pathogenesis of systemic lupus erythematosus (SLE) is characterized by complex immune dysfunction, including aberrant T-cell responses that result in tissue damage and terminal organ failure.
There is evidence from animal models of lupus nephritis that the combination of CTLA4-immunoglobulin (Ig)G plus cyclophosphamide can reverse this disease.
Approximately 50% of patients with systemic lupus erythematosus (SLE) have a serious infection during their disease course, and infections are the leading causes of hospitalization and mortality in these patients.
Increasing evidence suggests common genetic associations across a variety of autoimmune disorders, reflecting genuine susceptibility effects.
Page 4 of 4
Results 31 - 37 of 37
  •  Association for Value-Based Cancer Care
  • Value-Based Cancer Care
  • Value-Based Care in Rheumatology
  • Oncology Practice Management
  • Rheumatology Practice Management
  • Urology Practice Management
  • Inside Patient Care: Pharmacy & Clinic
  • Lynx CME